Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
2022studies shown
Showing 1,901-1,925 of 2,022
CompletedNCT02782442

Cognitive Training Delivered Remotely to Individuals With Psychosis (ROAM)

This study exists to understand how a guided support group holds up over time after the earliest research stage. Researchers are trying to understand whether a guided support group can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
University of Minnesota
Condition
Schizophrenia
CompletedNCT00716755

Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.

This study exists to compare options and see whether a medication treatment offers something meaningfully different. Researchers are trying to understand whether a medication treatment can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherOver 50 Years
Countries
Canada
Sponsor
Centre for Addiction and Mental Health
Condition
Schizophrenia
WithdrawnNCT05140135

Effectiveness and Mechanisms of Recovery Oriented Cognitive Therapy

This study exists to see whether a therapy or guided support program can play a useful role in care. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
University of Pennsylvania
Condition
Schizophrenia
CompletedNCT03133143

Video Games Among People With Schizophrenia

This study exists to see whether a digital app or remote support tool can make care clearer and more responsive. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
China
Sponsor
The Hong Kong Polytechnic University
Condition
Schizophrenia
CompletedNCT03559426

Research Into Antipsychotic Discontinuation and Reduction Trial

This study exists to understand how symptom tracking and monitoring holds up over time after the earliest research stage. Researchers are trying to understand whether symptom tracking and monitoring can better prevent setbacks and support longer-term stability.

SchizophreniaOtherOver 18 Years
Countries
United Kingdom
Sponsor
University College, London
Condition
Schizophrenia
TerminatedNCT03507127

Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1

This study exists to explore whether smoking support or smoking-related treatment could improve care and understanding. Researchers are trying to understand whether smoking support or smoking-related treatment can better prevent setbacks and support longer-term stability.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Brown University
Condition
Schizophrenia
TerminatedNCT03149107

"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"

This study exists to explore whether a therapy or guided support program could improve care and understanding. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 40 Years
Countries
Germany
Sponsor
University Hospital, Bonn
Condition
Schizophrenia
TerminatedNCT02746965

Magnetic Seizure Therapy for Schizophrenia

This study exists to understand whether a therapy or guided support program is both safe enough and useful enough to take further. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
China
Sponsor
Shanghai Mental Health Center
Condition
Schizophrenia
CompletedNCT00448630

An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics

This study exists to understand how this type of care holds up over time after the earliest research stage. Researchers are trying to understand what this type of care could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
Turkey
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Condition
Schizophrenia
TerminatedNCT03838484

Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

This study exists to compare options and see whether smoking support or smoking-related treatment offers something meaningfully different. Researchers are trying to understand whether smoking support or smoking-related treatment can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Vanderbilt University Medical Center
Condition
Schizophrenia
WithdrawnNCT05119894

A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia

This study exists to better understand the safety of the medication Brexpiprazole and how manageable it feels in practice. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

SchizophreniaOtherFrom 18 Years to 64 Years
Countries
Global
Sponsor
Otsuka Pharmaceutical Co., Ltd.
Condition
Schizophrenia
CompletedNCT04822883

Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia

This study exists to better understand the safety of the medication RL-007 and how manageable it feels in practice. Researchers are trying to understand whether the medication RL-007 can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
United States
Sponsor
Recognify Life Sciences
Condition
Schizophrenia
CompletedNCT05106309

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

This study exists to explore whether the medication CVL-231 could improve care and understanding. Researchers are trying to understand what the medication CVL-231 could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
Cerevel Therapeutics, LLC
Condition
Schizophrenia
CompletedNCT04510298

A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia

This study exists to compare options and see whether the medication SP-624 offers something meaningfully different. Researchers are trying to understand how people respond to the medication SP-624 in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
Sirtsei Pharmaceuticals, Inc.
Condition
Schizophrenia
CompletedNCT03969589

Reproductive Life Planning for Women With Mental Illness

This study exists to understand what helps a medication treatment work in everyday practice, not just under ideal conditions. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 40 Years
Countries
United States
Sponsor
VA Office of Research and Development
Condition
Schizophrenia
CompletedNCT02069925

STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand what helps a digital app or remote support tool stay useful, realistic, and easier to follow over time.

SchizophreniaOtherFrom 16 Years to 35 Years
Countries
United States
Sponsor
Yale University
Condition
Schizophrenia
CompletedNCT02864576

Cognitive Remediation Plus Aerobic Exercise in Schizophrenia Treatment

This study exists to compare options and see whether blood tests and biological markers offers something meaningfully different. Researchers are trying to understand whether blood tests and biological markers can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 28 Years to 60 Years
Countries
Spain
Sponsor
Parc de Salut Mar
Condition
Schizophrenia
CompletedNCT05320991

Effects of Ketamine on Mentalizing and Metacognition in Healthy Volunteers

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 35 Years
Countries
Germany
Sponsor
University Hospital, Bonn
Condition
Schizophrenia
CompletedNCT05229484

Effects of an Integrated Multimodal Lifestyle Intervention for Management of Violence in Schizophrenia

This study exists to compare options and see whether psychoeducation, a guided learning and support program, offers something meaningfully different. Researchers are trying to understand whether psychoeducation, a guided learning and support program, can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 20 Years to 65 Years
Countries
Taiwan
Sponsor
I-Shou University
Condition
Schizophrenia
CompletedNCT03699501

Psychometric Validation of an Oral Health-related Scale for Quality of Life and Coping in People With Schizophrenia

This study exists to learn from real-world information that can show how questionnaires and follow-up reports fits into care. Researchers are trying to understand what questionnaires and follow-up reports could change in day-to-day care and decision-making.

SchizophreniaOtherOver 18 Years
Countries
France
Sponsor
Centre Hospitalier Universitaire Dijon
Condition
Schizophrenia